← board
DWTX
Dogwood Therapeutics Inc.distress 9/10 · high distress / dilution risk$1.46+4%today-82% from 52w high
Neurology 1
Lead: Chemotherapy-induced pain and neuropathy
Revenue
pre-revenue
Liquidity
$13M
Runway
0.8 yrs
Shares 1y
+1660%
Price & events
-52.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.3%
1D
+1.4%
1W
-5.2%
1M
-4.6%
3M
-52.4%
6M
-68.9%
1Y
-74.4%
2Y
-99.0%
5Y
-99.2%
All
Overview
- Market Cap
- $49.10M
- Volume
- 170.60K
- 52 Week Range
- $1.34 – $7.91
- Total Shares
- 33.63M
- Float Shares
- 5.30M
- Short %
- 0.82%
- % Held by Insiders
- 73.35%
- % Held by Institutions
- 10.97%
- RVOL
- 1.70x
- Beta
- 1.71
Pipeline stages · 1 programs
Halneuron, Halneuron (Open Label Extension)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07 | Phase 2 | Halneuron, Halneuron (Open Label Extension) | Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain | 240 | recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 9
- towards the end of 2026Guided 70%regulatory submissionFiled (NDA/BLA)Halneuron · Submit end of Phase 2 summary, manufacturing plans, and Phase 3 plans to FDASEC 8-K
- Q3 2026Guided 70%readoutPhase 2Halneuron · Projected release of final Phase 2b data from HALT-CINP studySEC 8-K
- mid-2026trial initiationsecondaryPhase 1SP16 IV · Commence dosing in Phase 1b studySEC 8-K
- Q1 2026regulatory submissionFiled (NDA/BLA)SP16 IV · File IND for SP16 IV with FDASEC 8-K
- 2026-03-26fda agreementSP16 IV · IND filed for SP16 IVSEC 8-K
- 2026-03-26partnershipSP16 IV · Royalty-free global development and commercialization license for cancer-related pain and neuropathySEC 8-K
- Q4 2025readoutPhase 2Halneuron · Interim data from Phase 2b CINP trialSEC 8-K
- 2025-09-29partnershipSP16 · Dogwood Therapeutics entered into exclusive licensing agreement with Serpin Pharma for IV formulation of SP16, a LRP1 agonist for chemotherapy-induced peripheral neuropathy.SEC 8-K
- mid-November 2024readoutPhase 2IMC-2 · Top-line results from phase 2a studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-19HC Wainwright & Co.Buy
- 2026-04-27HC Wainwright & Co.Buy
- 2026-02-20HC Wainwright & Co.Buy
- 2026-01-30HC Wainwright & Co.Buy
- 2025-09-30HC Wainwright & Co.Buy
- 2025-04-23HC Wainwright & Co.Neutral → Buy
Competitors — Chemotherapy-induced pain and neuropathy
- none identified
Recent news
- 2026-07-20Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial - marketscreener.com
- 2026-07-20Dogwood (DWTX) Reaches Enrollment Milestone in HAL-CINP Phase 2b Trial - GuruFocus
- 2026-07-20Dogwood Therapeutics enrolls 200 patients in pain treatment trial - Investing.com
- 2026-07-20Dogwood Enrolls First 200 Patients in Ongoing Halneuron® - GlobeNewswire
- 2026-07-20Dogwood Enrolls First 200 Patients in Ongoing Halneuron® - GlobeNewswire
- 2026-07-20Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026 - Yahoo Finance
- 2026-07-20Dogwood Reports 4.5% Early Termination Rate Among First 200 Patients - Stock Titan
- 2026-07-20Dogwood Enrolls First 200 Patients in Ongoing Halneuron® - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.